S6K1 Amplification Confers Innate Resistance to CDK4/6 Inhibitors through Activating C-myc Pathway in Patients with Estrogen Receptor-Positive Breast Cancer

0
160
Investigators elucidated the molecular hallmarks and therapeutically actionable features of patients with resistance to CDK4/6 inhibitors.
[Molecular Cancer]
Abstract